| Name | MBQ-167 |
| Description | MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively). |
| In vitro | MBQ-167 causes this phenotype in multiple mesenchymal cancer cell types including GFP-HER2-BM, MDA-MB-468, and Hs578t human breast cancer cells, as well as Mia-PaCa-2 pancreatic cancer cells, SKOV3 ovarian cancer cells, AGS and NCI-N87 gastric cancer cells, and SH-SY5Y neuroblastoma cells. MBQ-167 (≥100 nM) causes a loss of polarity in metastatic breast cancer cells. MBQ-167(500 nM; 24 h)treatment, results in ~95% cell rounding and detachment from the substratum in metastatic MDA-MB-231 cells. At earlier times (6h), MBQ-167(250 or 500 nM)treatment, induce an inhibition in Rac activity in the attached cell population, while the detached population demonstrates a ~40-50% inhibition. The attached population of MDA-MB-231 cells demonstrate a ~25% decrease in Rac activation while the detached cells are more responsive with a ~75% decrease following treatment with 250 nM MBQ-167 for 24 h . |
| In vivo | Mice treated with MBQ-167 exhibited comparable doubling times for the treatments (10 and 11 days), and demonstrated a statistically significant decrease in tumor growth. Upon sacrifice, a dosage of 1.0 mg/kg body weight (BW) with MBQ-167 led to an approximate 80% reduction in tumor size, while a higher dose of 10 mg/kg BW achieved an approximate 95% reduction. In comparison, EHop-016 at a 10 mg/kg BW dosage resulted in about a 40% reduction in tumor growth, making MBQ-167 ten times more effective than EHop-016. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 0.1 mg/mL (insoluble)
DMSO : 155 mg/mL (458.02 mM), Sonication is recommended.
|
| Keywords | Ras 1/2/3 | Ras | MBQ-167 | MBQ167 | MBQ 167 | Inhibitor | inhibit | Cyclin dependent kinase | CDK | Cdc42 |
| Inhibitors Related | Ribociclib | Adagrasib | 2-Chloropyrazine | Kojic acid | RMC-9805 | (R)-Naproxen | Abemaciclib | MRTX1133 | 2,4,6-Trihydroxybenzoic acid | Sotorasib | Palbociclib | Daraxonrasib |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
